{"id":"iac-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":null,"effect":"Nephrotoxicity (cisplatin-related)"},{"rate":null,"effect":"Hemorrhagic cystitis (ifosfamide-related)"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IAC is a multi-agent chemotherapy regimen combining three cytotoxic drugs with complementary mechanisms: ifosfamide (alkylating agent), doxorubicin (topoisomerase II inhibitor and intercalating agent), and cisplatin (platinum-based alkylating agent). Together, these agents create multiple forms of DNA damage to achieve synergistic anti-tumor effects, particularly in sarcomas and other solid tumors.","oneSentence":"IAC regimen is a chemotherapy combination that uses ifosfamide, doxorubicin, and cisplatin to damage cancer cell DNA and inhibit tumor growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:09.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Soft tissue sarcoma"},{"name":"Osteosarcoma"},{"name":"Other solid tumors (investigational)"}]},"trialDetails":[{"nctId":"NCT06744504","phase":"PHASE3","title":"Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-10","conditions":"AML, RUNX1-RUNX1T1 Fusion Protein Expression","enrollment":300},{"nctId":"NCT02937662","phase":"PHASE2","title":"Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-10","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06529250","phase":"NA","title":"Intermediate-dose HAD Regimen for CEBPA Double-mutated AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-13","conditions":"AML","enrollment":148},{"nctId":"NCT02323022","phase":"PHASE3","title":"Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2014-12","conditions":"Acute Myeloid Leukemia","enrollment":618},{"nctId":"NCT02676856","phase":"NA","title":"Hematopoietic Stem Cell Microtransplantation for in AML","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02","conditions":"Acute Myeloid Leukemia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IAC regimen","genericName":"IAC regimen","companyName":"The First Affiliated Hospital of Soochow University","companyId":"the-first-affiliated-hospital-of-soochow-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IAC regimen is a chemotherapy combination that uses ifosfamide, doxorubicin, and cisplatin to damage cancer cell DNA and inhibit tumor growth. Used for Soft tissue sarcoma, Osteosarcoma, Other solid tumors (investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}